Parametrica Management’s Neurocrine Biosciences NBIX Stock Holding History

Parametrica Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-3,316	Closed	-$408K	–	306
2018 Q3	$408K	Buy	+3,316	New	+$376K	0.89%	19
2017 Q1	–	Sell	-8,505	Closed	-$329K	–	328
2016 Q4	$329K	Buy	+8,505	New	+$385K	0.33%	132
2014 Q4	–	Sell	-11,222	Closed	-$176K	–	64
2014 Q3	$176K	Buy	+11,222	New	+$168K	1.02%	51

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Parametrica Management's NBIX Position: Q4 2018 in Review

Parametrica Management sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 3,316 shares — an estimated $408K sold.

Parametrica Management first reported a position in NBIX in Q3 2014 and held it in 3 quarters. The position peaked at $408K in Q3 2018. 330 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

Parametrica Management reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
Parametrica Management sold 3,316 Neurocrine Biosciences shares in Q4 2018, an estimated $408K.
Parametrica Management first reported a position in Neurocrine Biosciences in Q3 2014 and held it in 3 quarters.
Parametrica Management's Neurocrine Biosciences position peaked at $408K in Q3 2018.
330 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Parametrica Management's 13F filing for Q4 2018, filed 12 Feb 2019.